心房颤动
心力衰竭
医学
氧化应激
心脏病学
重症监护医学
内科学
病因学
纤维化
活性氧
生物化学
化学
作者
Alfredo Mauriello,Antonia Ascrizzi,Anna Selvaggia Roma,Riccardo Molinari,Alfredo Caturano,Egidio Imbalzano,Antonello D’Andrea,Vincenzo Russo
出处
期刊:Antioxidants
[MDPI AG]
日期:2024-07-02
卷期号:13 (7): 806-806
被引量:13
标识
DOI:10.3390/antiox13070806
摘要
Heart failure (HF) and atrial fibrillation (AF) are prevalent cardiovascular diseases that contribute significantly to morbidity, mortality, hospitalisation, and healthcare costs. It is not uncommon for these conditions to coexist and have mutually reinforcing effects. A critical factor in the aetiology of these conditions is oxidative stress, driven by reactive oxygen species (ROS), which contributes to atrial remodelling and fibrosis. The recent introduction of new drugs for the treatment of heart failure has also had an impact on the management of atrial fibrillation due to their influence on oxidative stress. The objective of this review is to analyse the effects of these therapies, including their role in mitigating ROS, on the prevention and treatment of AF in HF patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI